Logo
x

Search category

Subscribe Now

Merck KGaA

Merck KGaA Reports Results for Evobrutinib in P-III Trial for the Treatment of Relapsing Multiple Sclerosis (RMS)

Merck KGaA Reports Results for Evobrutinib in P-III Trial for the Treatment of Relapsing Multiple Sclerosis (RMS)

  • December 6, 2023
Merck KGaA and Hengrui Pharma Entered into a Licensing Agreement to Develop and Commercialize HRS-1167 and SHR-A1904 to Treat Cancer

Merck KGaA and Hengrui Pharma Entered into a Licensing Agreement to Develop and Commercialize HRS-1167 and SHR-A1904 to Treat Canc...

  • October 31, 2023
Merck KGaA Reports P-III Trial (JAVELIN Bladder 100) Results of Bavencio (avelumab) in 1L Maintenance Treatment for Advanced Urothelial Carcinoma

Merck KGaA Reports P-III Trial (JAVELIN Bladder 100) Results of Bavencio (avelumab) in 1L Maintenance Treatment for Advanced Uroth...

  • February 14, 2023
Merck KGaA Entered into Option to License Agreement with Nerviano Medical Sciences to Develop NMS-293

Merck KGaA Entered into Option to License Agreement with Nerviano Medical Sciences to Develop NMS-293

  • September 21, 2022
Top 20 BioPharma Companies based on 2021 Total Revenue

Top 20 BioPharma Companies based on 2021 Total Revenue

  • April 14, 2022
PharmaShots Weekly Snapshots (November 15 - 19, 2021)

PharmaShots Weekly Snapshots (November 15 - 19, 2021)

  • November 19, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.